An email exchange attached as part of the filing shows that Bafna, in his resignation communication dated December 3 to chief financial officer Sumeet Sood, cited Delhi’s pollution levels as the reason for stepping down from his role and requested to be relieved at the earliest.
In its response, the company acknowledged the resignation and said it would not be in a position to persuade him to continue, referring to his health issues, and confirmed the effective date of his release from duties.
Bafna had joined Akums Drugs as President–Finance with effect from August 8, 2025, according to an earlier exchange announcement. Bafna previously served as Chief Financial Officer and Key Managerial Personnel of Heranba Industries Limited, resigning from that role effective June 30, 2025, after more than four years with the agrochemical firm.Akums Drugs, one of India’s largest pharmaceutical contract manufacturing organisations, did not independently attribute the resignation to pollution in its exchange disclosure, instead stating that the decision was driven by health-related concerns, in line with regulatory norms.
Bafna’s resignation comes against the backdrop of severe air pollution in the national capital during late November and early December, when air quality in several parts of Delhi remained in the very poor to severe categories. Delhi typically experiences a sharp deterioration in air quality during winter due to vehicular emissions, industrial activity, construction dust and unfavourable meteorological conditions.
Over the years, worsening air quality in the capital has triggered repeated public health advisories and emergency measures, with medical experts warning of increased respiratory and cardiovascular risks from prolonged exposure.
Akums Drugs has not announced an immediate successor to Bafna and did not comment further beyond the exchange disclosure.
